The molecular background of mucinous carcinoma beyond MUC2

Journal of Pathology: Clinical Research

Volumn 1, Issue 1, 2015, Pages 3-17

  Hugen, Niek ^a   Simons, Michiel ^a   Halilović, Altuna ^a   van der Post, Rachel S ^a   Bogers, Anna J ^a   Marijnissen van Zanten, Monica AJ ^a   de Wilt, Johannes HW ^a   Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

colorectal carcinoma; genotype; molecular pathology; mucinous carcinoma; phenotype

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN;

BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER CLASSIFICATION; COLLOID CARCINOMA; COLORECTAL CARCINOMA; COLORECTAL COLLOID CARCINOMA; COMPARATIVE STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GALLBLADDER CARCINOMA; GENETIC VARIABILITY; GENOME; HUMAN; LUNG CARCINOMA; MAPK SIGNALING; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MUCINOUS BILE DUCT CARCINOMA; MUCINOUS BREAST CARCINOMA; MUCINOUS GALLBLADDER CARCINOMA; MUCINOUS GASTRIC CARCINOMA; MUCINOUS LUNG CARCINOMA; MUCINOUS NONCYSTIC PANCREAS CARCINOMA; MUCINOUS OVARY CARCINOMA; MUTATION; OVARY CARCINOMA; PANCREAS CARCINOMA; PHENOTYPE; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH CARCINOMA; THERAPY RESISTANCE;

EID: 84940450185     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.1     Document Type: Review

References (171)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
2. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System (4th edn). International Agency for Research on Cancer: Lyon, 2010.
3. Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012; 19: 2814–2821.
4. Hugen N, Verhoeven RH, Radema SA, et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol 2013; 24: 2819–2824.
5. Negri FV, Wotherspoon A, Cunningham D, et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305–1310.
6. Mekenkamp LJ, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012; 48: 501–509.
7. Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881–887.
8. Hugen N, van de Velde CJ, de Wilt JH, et al. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014; 25: 651–657.
9. Hanski C, Hofmeier M, Schmitt-Graff A, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 1997; 182: 385–391.
10. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
12. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004; 23: 77–99.
13. Weiss AA, Babyatsky MW, Ogata S, et al. Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem 1996; 44: 1161–1166.
14. Park SY, Lee HS, Choe G, et al. Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location. Virchows Arch 2006; 449: 40–47.
15. You JF, Hsieh LL, Changchien CR, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res 2006; 12: 4244–4250.
16. Tozawa E, Ajioka Y, Watanabe H, et al. Mucin expression, p53 overexpression, and peritumoral lymphocytic infiltration of advanced colorectal carcinoma with mucus component: is mucinous carcinoma a distinct histological entity? Pathol Res Pract 2007; 203: 567–574.
17. Li L, Huang PL, Yu XJ, et al. Clinicopathological significance of mucin 2 immuno-histochemical expression in colorectal cancer: a meta-analysis. Chin J Cancer Res 2012; 24: 190–195.
18. Okudaira K, Kakar S, Cun L, et al. MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010; 36: 765–775.
19. Hugen N, van Beek JJ, de Wilt JH, et al. Insight into mucinous colorectal carcinoma: clues from etiology. Ann Surg Oncol 2014; epub ahead of print (PMID 24728741).
20. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073–2087, e2073.
21. Kim H, Jen J, Vogelstein B, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994; 145: 148–156.
22. Bocker T, Schlegel J, Kullmann F, et al. Genomic instability in colorectal carcinomas: comparison of different evaluation methods and their biological significance. J Pathol 1996; 179: 15–19.
23. Gafa R, Maestri I, Matteuzzi M, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89: 2025–2037.
24. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107–2116.
25. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376–1387.
26. Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003; 27: 1407–1417.
27. Sarli L, Bottarelli L, Azzoni C, et al. Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 2004; 40: 1581–1588.
28. Mori S, Ogata Y, Shirouzu K. Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 2004; 9: 322–329.
29. Chang SC, Lin JK, Yang SH, et al. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006; 118: 1721–1727.
30. Meng WJ, Sun XF, Tian C, et al. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients. Oncology 2007; 72: 82–88.
31. Ashktorab H, Brim H, Al-Riyami M, et al. Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci 2008; 53: 2723–2731.
32. Kim YH, Min BH, Kim SJ, et al. Difference between proximal and distal microsatellite-unstable sporadic colorectal cancers: analysis of clinicopathological and molecular features and prognoses. Ann Surg Oncol 2010; 17: 1435–1441.
33. Kakar S, Deng G, Smyrk TC, et al. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. Mod Pathol 2012; 25: 1040–1047.
34. Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013; 19: 3285–3296.
35. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Familial Cancer 2004; 3: 93–100.
36. Leopoldo S, Lorena B, Cinzia A, et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008; 15: 1429–1439.
37. Messerini L, Ciantelli M, Baglioni S, et al. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol 1999; 30: 629–634.
38. Kakar S, Aksoy S, Burgart LJ, et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 2004; 17: 696–700.
39. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988–993.
40. Tanaka H, Deng G, Matsuzaki K, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 2006; 118: 2765–2771.
41. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96: 8681−8686.
42. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837–845.
43. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PloS One 2008; 3: e3698.
44. Min BH, Bae JM, Lee EJ, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11: 344.
45. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293–297.
46. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–532.
47. Sammoud S, Khiari M, Semeh A, et al. Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Appl Immunohistochem Mol Morphol 2012; 20: 146–152.
48. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36: 744–752.
49. Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23: 5635–5643.
50. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59–68.
51. Garrido-Laguna I, Hong DS, Janku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PloS One 2012; 7: e38033.
52. Gunal A, Hui P, Kilic S, et al. KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol 2013; 47: 509–514.
53. Selcukbiricik F, Bilici A, Tural D, et al. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol 2013; 34: 2233–2239.
54. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438–1446.
55. Abubaker J, Bavi P, Al-Haqawi W, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435–445.
56. Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367–380.
57. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathol 2013; 26: 825–834.
58. Mao C, Zhou J, Yang Z, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PloS One 2012; 7: e36653.
59. Li HT, Lu YY, An YX, et al. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 2011; 25: 1691–1697.
60. Laurent-Puig P, Olschwang S, Delattre O, et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int J Cancer 1991; 49: 220–223.
61. Zhang H, Nordenskjold B, Dufmats M, et al. K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa. Eur J Cancer 1998; 34: 2053–2057.
62. Akkiprik M, Celikel CA, Dusunceli F, et al. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. Turk J Gastroenterol 2008; 19: 22–27.
63. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
64. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98–99.
65. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954.
66. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584–4594.
67. Kawasaki T, Ohnishi M, Suemoto Y, et al. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008; 21: 150–158.
68. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191–195.
69. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63: 5209–5212.
70. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.
71. Abubaker J, Bavi P, Al-Harbi S, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27: 3539–3545.
72. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534–541.
73. Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PloS One 2013; 8: e65479.
74. Voutsina A, Tzardi M, Kalikaki A, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013; 26: 302–313.
75. Eklof V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013; 108: 2153–2163.
76. Hatayama H, Iwashita J, Kuwajima A, et al. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem Biophys Res Commun 2007; 356: 599–603.
77. Lee HY, Crawley S, Hokari R, et al. Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway. Int J Oncol 2010; 36: 941–953.
78. Ahn DH, Crawley SC, Hokari R, et al. TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem 2005; 15: 29–40.
79. Iwashita J, Sato Y, Sugaya H, et al. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003; 81: 275–282.
80. Song S, Byrd JC, Koo JS, et al. Bile acids induce MUC2 overexpression in human colon carcinoma cells. Cancer 2005; 103: 1606–1614.
81. Walsh MD, Clendenning M, Williamson E, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 2013; 26: 1642–1656.
82. Adachi Y, Mori M, Kido A, et al. A clinicopathologic study of mucinous gastric carcinoma. Cancer 1992; 69: 866–871.
83. Kunisaki C, Akiyama H, Nomura M, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol 2006; 13: 836–842.
84. Yan C, Zhu ZG, Yan M, et al. Clinicopathological characteristics and computed tomography features of mucinous gastric carcinoma. J Int Med Res 2011; 39: 291–301.
85. Yasuda K, Adachi Y, Shiraishi N, et al. Pathology and prognosis of mucinous gastric carcinoma. J Surg Oncol 2001; 76: 272–277.
86. Choi JS, Kim MA, Lee HE, et al. Mucinous gastric carcinomas: clinicopathologic and molecular analyses. Cancer 2009; 115: 3581–3590.
87. Wu M, Semba S, Li D, et al. Molecular pathological analysis of mucinous adenocarcinomas of the stomach. Pathobiology 2004; 71: 201–210.
88. Wirtz HC, Muller W, Noguchi T, et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res 1998; 4: 1749–1754.
89. Solcia E, Klersy C, Mastracci L, et al. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch 2009; 455: 197–211.
90. Seo HM, Chang YS, Joo SH, et al. Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype. J Surg Oncol 2009; 99: 143–147.
91. Falchetti M, Saieva C, Lupi R, et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925–932.
92. Kim H, An JY, Noh SH, et al. High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol 2011; 26: 585–592.
93. Schneider BG, Bravo JC, Roa JC, et al. Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population. Int J Cancer 2000; 89: 444–452.
94. Sung CO, Lee SM, Choi JS, et al. Tumor size predicts survival in mucinous gastric carcinoma. J Surg Oncol 2012; 106: 757–764.
95. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285–291.
96. Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52: 738–746.
97. Liu Z, Liu L, Li M, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology 2011; 43: 234–238.
98. Adsay NV, Merati K, Nassar H, et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol 2003; 27: 571–578.
99. Adsay NV, Pierson C, Sarkar F, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 2001; 25: 26–42.
100. Terris B, Dubois S, Buisine MP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol 2002; 197: 632–637.
101. Luttges J, Beyser K, Pust S, et al. Pancreatic mucinous noncystic (colloid) carcinomas and intraductal papillary mucinous carcinomas are usually microsatellite stable. Mod Pathol 2003; 16: 537–542.
102. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002; 8: 3156–3163.
103. Dursun N, Escalona OT, Roa JC, et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas. Arch Pathol Lab Med 2012; 136: 1347–1358.
104. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 2005; 97: 519–523.
105. Lurie G, Wilkens LR, Thompson PJ, et al. Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis. Gynecol Oncol 2010; 119: 278–284.
106. Chen T, Jansen L, Gondos A, et al. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur J Cancer Prev 2013; 22: 59–67.
107. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 2011; 205: 480 e481–488.
108. Ji J, Forsti A, Sundquist J, et al. Survival in ovarian cancer patients by histology and family history. Acta Oncol 2008; 47: 1133–1139.
109. Tavassoli FA, Devilee P (eds). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. International Agency for Research on Cancer: Lyon, 2003.
110. Varras MN, Sourvinos G, Diakomanolis E, et al. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology 1999; 56: 89–96.
111. Hogdall EV, Hogdall CK, Blaakaer J, et al. K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study. Gynecol Oncol 2003; 89: 31–36.
112. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883–887.
113. Enomoto T, Weghorst CM, Inoue M, et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777–785.
114. Auner V, Kriegshauser G, Tong D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009; 9: 111.
115. Mandai M, Konishi I, Kuroda H, et al. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 1998; 29: 34–40.
116. Suzuki M, Ohwada M, Saga Y, et al. Are DNA mismatch repair deficiencies responsible for accumulation of genetic alterations in epithelial ovarian cancers? Cancer Genet Cytogenet 2001; 124: 152–158.
117. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336–340.
118. Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 2013; 95: 235–241.
119. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378–381.
120. Huan Z, Nakayama K, Nakayama N, et al. Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival. Oncol Rep 2008; 19: 775–781.
121. Geisler JP, Goodheart MJ, Sood AK, et al. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 2003; 98: 2199–2206.
122. Dellas A, Puhl A, Schraml P, et al. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Anticancer Res 2004; 24: 361–369.
123. Roh HJ, Suh DS, Choi KU, et al. Inactivation of O(6)-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types. J Obstet Gynaecol Res 2011; 37: 851–860.
124. Lu FI, Gilks CB, Mulligan AM, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol 2012; 31: 524–531.
125. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678–7681.
126. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095–2097.
127. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 2006; 103: 692–697.
128. Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet 2011; 284: 1283–1288.
129. de Waal YR, Thomas CM, Oei AL, et al. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 2009; 19: 1160–1165.
130. Yemelyanova AV, Vang R, Judson K, et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 2008; 32: 128–138.
131. Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 2004; 93: 87–91.
132. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol 2011; 6: 244–285.
133. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004; 28: 442–452.
134. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012; 18: 1947–1953.
135. Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013; 79: 8–13.
136. Liu B, Shi SS, Wang X, et al. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification]. Chin J Pathol 2012; 41: 505–510.
137. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111: 541–547.
138. Zhang M, Teng XD, Guo XX, et al. Clinicopathological characteristics and prognosis of mucinous breast carcinoma. J Cancer Res clinical oncology 2013.
139. Tseng HS, Lin C, Chan SE, et al. Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women. World J Surg Oncol 2013; 11: 139.
140. Bae SY, Choi MY, Cho DH, et al. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer 2011; 14: 308–313.
141. Fujii H, Anbazhagan R, Bornman DM, et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat 2002; 76: 255–260.
142. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009; 22: 1401–1414.
143. Horlings HM, Weigelt B, Anderson EM, et al. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257–269.
144. Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282–298.
145. Matsukita S, Nomoto M, Kitajima S, et al. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 2003; 42: 26–36.
146. Cao AY, He M, Liu ZB, et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol 2012; 19: 3019–3027.
147. Hsu YH, Shaw CK. Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. Kaohsiung J Med Sci 2005; 21: 197–202.
148. Cho LC, Hsu YH. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung J Med Sci 2008; 24: 227–232.
149. Park S, Koo J, Kim JH, et al. Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified. J Korean Med Sci 2010; 25: 361–368.
150. Zhou F, Li S, Meng HM, et al. MicroRNA and histopathological characterization of pure mucinous breast carcinoma. Cancer Biol Med 2013; 10: 22–27.
151. Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999; 17: 1442–1448.
152. Kehr EL, Jorns JM, Ang D, et al. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol 2012; 43: 2207–2212.
153. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene 2008; 27: 5648–5650.
154. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006; 208: 350–355.
155. Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 2010; 88: 150–155.
156. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007; 13: 408–414.
157. Michelucci A, Di Cristofano C, Lami A, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009; 18: 200–205.
158. Santarpia L, Qi Y, Stemke-Hale K, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012; 134: 333–343.
159. Tong L, Yang XX, Liu MF, et al. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pacific J Cancer Prev 2012; 13: 5599–5603.
160. Adem C, Soderberg CL, Cunningham JM, et al. Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 2003; 107: 580–582.
161. Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin Cancer Res 1999; 5: 839–844.
162. Halford SE, Sawyer EJ, Lambros MB, et al. MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol 2003; 201: 389–394.
163. Lacroix-Triki M, Lambros MB, Geyer FC, et al. Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol 2010; 4: 22–31.
164. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993; 53: 5853–5855.
165. Toyama T, Iwase H, Yamashita H, et al. Microsatellite instability in sporadic human breast cancers. Int J Cancer 1996; 68: 447–451.
166. Perrais M, Pigny P, Copin MC, et al. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002; 277: 32258–32267.
167. Bai Z, Zhang Z, Ye Y, et al. Sodium butyrate induces differentiation of gastric cancer cells to intestinal cells via the PTEN/phosphoinositide 3-kinase pathway. Cell Biol Int 2010; 34: 1141–1145.
168. Catalano V, Loupakis F, Graziano F, et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol 2012; 23: 135–141.
169. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247–257.
170. Oberholzer K, Menig M, Kreft A, et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. Int J Rad Oncol Biol Phys 2012; 82: 842–848.
171. Shin US, Yu CS, Kim JH, et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol 2011; 18: 2232–2239.